Ascites
For patient information click here
For the approach to a patient with ascites, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Synonyms and keywords: Peritoneal cavity fluid, Peritoneal fluid excess, Hydroperitoneum, Abdominal dropsy, Excess peritoneal fluid.
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Ascites is defined as fluid accumulation of more than 25 mL in the peritoneal cavity. Ascites may be classified according to etiology into four groups include portal hypertension, hypoalbuminemia, peritoneal disease, and other diseases. Ascites is also classified based on the Serum-ascites albumin gradient (SAAG) as two subtypes include transudate – SAAG > 1.1 g/dL and exudate – SAAG < 1.1 g/dL. Ascites is excess accumulation of fluid in the peritoneal cavity. The fluid can be defined as a transudate or an exudate. Amounts of up to 25 liters are fully possible. Roughly, transudates are a result of increased pressure in the portal vein (> 8 mmHg), such as cirrhosis; while exudates are actively secreted fluid due to inflammation or malignancy. The most useful measure is the difference between ascitic and serum albumin concentrations. A difference of less than 1.1 g/dl (10 g/L) implies an exudate. There is no genetic background for ascites. On gross pathology, clear to pale yellow fluid accumulation in peritoneal space are characteristic findings of ascites under normal condition, but it may be chylous, psudochylous, or bloody. Paracentesis is sampling ascites fluid through abdominal wall with overall complication rate of not more than 1%. The sampled fluid will be surveyed upon total protein concentration, neutrophil count, and inoculation into blood culture bottles. The mainstays of first-line treatment of patients with cirrhosis and ascites include (1) education regarding dietary sodium restriction (2000 mg per day [88 mmol per day]) and (2) oral diuretics. Medical therapy is based on different grades of ascites. Medical therapy would inhibit different processes in pathophysiology of ascites. First-line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol per day [2000 mg per day], diet education), and diuretics (oral spironolactone with or without oral furosemide).
Historical Perspective
About 20 BC, Aulus Cornelius Celsus (A.D. 30), a Roman encyclopedist explained in his book “De Medicina” three different types of fluid accumulation under the skin; which was called hydrops by Greeks. Celsus postulated that ascites is mostly secondary to quartan fever (malaria) in Rome. The principles of treatment for ascites were explained as thirst, rest, and abstinence. Drinking less fluid and sweating more, not with exercise, but with heated sand, or in the sweating-room, or with a dry oven and such- like were the other alternative therapies. In 1827, Ludwig van Beethoven involved in ascites and underwent large volumes of paracenteses. His physician write about him as “Beethoven had almost immediate relief, and when he saw the stream of water [during paracentesis], cried out that the operation made him think of Moses, who struck the rock with his staff and made the water gush forth“.
Classification
Ascites may be classified according to etiology into four groups include portal hypertension, hypoalbuminemia, peritoneal disease, and other diseases. Ascites is also classified based on the Serum-ascites albumin gradient (SAAG) as two subtypes include transudate – SAAG > 1.1 g/dL and exudate – SAAG < 1.1 g/dL.
Pathophysiology
Ascites is excess accumulation of fluid in the peritoneal cavity. The fluid can be defined as a transudate or an exudate. Amounts of up to 25 liters are fully possible. Roughly, transudates are a result of increased pressure in the portal vein (> 8 mmHg), such as cirrhosis; while exudates are actively secreted fluid due to inflammation or malignancy. The most useful measure is the difference between ascitic and serum albumin concentrations. A difference of less than 1.1 g/dl (10 g/L) implies an exudate. There is no genetic background for ascites. On gross pathology, clear to pale yellow fluid accumulation in peritoneal space are characteristic findings of ascites under normal condition, but it may be chylous, psudochylous, or bloody.
Causes
Life threatening causes of ascites are acute liver failure, hepatic failure, and hepatorenal syndrome. Common causes of ascites are Budd-Chiari syndrome, malignancy, and cirrhosis. Less common causes of ascites are the conditions which may lead to fetal ascites, neonatal ascites, and infantile ascites.
Differentiating Ascites from Other Diseases
Diseases that cause ascites should differentiate from each others, such as cirrhosis, Alcoholic hepatitis, Budd-Chiari syndrome, Constrictive pericarditis, Heart failure, Myxedema, Cancer, Nephrotic syndrome, Pancreatitis, Serositis, and Tuberculosis. The ascites may be transudate (serum-ascites albumin gradient [SAAG] ≥ 1.1 g/dL) or exudate (serum-ascites albumin gradient [SAAG] < 1.1 g/dL).
Epidemiology and Demographics
The incidence of ascites is approximately 60,000 per 100,000 individuals with cirrhosis worldwide. The incidence of ascites is approximately 75,000 per 100,000 cirrhotic individuals with a mortality rate of 50%, within 3 years. Patients of all age groups may develop ascites. Cirrhotic ascites usually affects individuals of the non-Hispanic blacks and Mexican Americans race. Males are more commonly affected by cirrhotic ascites than females. The male to female ratio is approximately 2.5 to 1.
Risk Factors
The most potent risk factor in the development of ascites is cirrhosis. Other risk factors include malignancy, heart failure, and tuberculosis. Common risk factors in the development of asctes include acute liver failure, hepatorenal syndrome, liver fibrosis, Budd-Chiari syndrome, constrictive pericarditis, nephrotic syndrome, pancreatitis, and serositis.
Screening
There is insufficient evidence to recommend routine screening for ascites.
Natural History, Complications, and Prognosis
More than half of the patients with cirrhosis would involve with ascites during the disease. If left untreated, 11.4% of patients with cirrhotic ascites may progress to develop hepatorenal syndrome during 5 years. Common complications of ascites include spontaneous bacterial peritonitis (SBP), dilutional hyponatremia, and hepatorenal syndrome. Prognosis is generally poor, and the 5-year survival rate of patients with cirrhotic ascites is approximately 56.6%.
Diagnosis
History and Symptoms
The hallmark of ascites is abdominal distention. A positive history of cirrhosis and liver failure is suggestive of ascites. The most common symptoms of ascites include abdominal discomfort, shortness of breath, and weight gain.
Physical Examination
Physical examination of patients with ascites is usually remarkable for flank dullness, shifting dullnes, and fluid wave. The presence of decreased breath sounds or dull percussion in lower chest on physical examination is diagnostic of pleural effusion beside ascites.
Laboratory Findings
The only diagnostic laboratory finding associated with ascites is serum-ascites albumin gradient (SAAG). SAAG is defined as the difference between albumin level in serum and ascites. Other diagnostic laboratory findings may reveal the underlying causes of ascites. Cirrhosis, as the most common cause of ascites, reveals elevated liver enzymes, creatinine, international normalized ratio (INR) along with decreased albumin, platelet count, hemoglobin (anemia), and white blood cell (WBC) count.
Electrocardiogram
There are no ECG findings associated with ascites.
X-ray
An abdominal X-ray may be helpful in the diagnosis of ascites. Findings on an abdominal X-ray suggestive of ascites include increased density in abdomen diffusely, lack of shadow differentiation between different soft tissues in abdomen, displacement of intestines and viscera medially, and flank bulging.
CT scan
Abdominal CT scan may be helpful in the diagnosis of ascites. Findings on CT scan suggestive of ascites include fluid accumulation within abdominal cavity, defined as transudate (same density as water), exudate (more density than water), and hemoperitoneum (density as ~45 HU).
MRI
There are no MRI findings associated with ascites.
Ultrasound
Ultrasound may be helpful in the diagnosis of ascites. Findings on an ultrasound diagnostic of ascites include anechoic fluid accumulation in abdominal cavity (simple transudate ascites), fluid accumulation along with floating debris (exudative, hemoperitoneum, or malignant ascites), and fluid accumulation along with septations (inflammatory or malignant ascites).
Other Imaging Findings
There are no other imaging findings associated with ascites.
Other Diagnostic Studies
Paracentesis is sampling ascites fluid through abdominal wall with overall complication rate of not more than 1%. The sampled fluid will be surveyed upon total protein concentration, neutrophil count, and inoculation into blood culture bottles.
Treatment
Medical Therapy
The mainstays of first-line treatment of patients with cirrhosis and ascites include (1) education regarding dietary sodium restriction (2000 mg per day [88 mmol per day]) and (2) oral diuretics. Medical therapy is based on different grades of ascites. Medical therapy would inhibit different processes in pathophysiology of ascites. First-line treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol per day [2000 mg per day], diet education), and diuretics (oral spironolactone with or without oral furosemide).
Surgery
Surgery is the mainstay of treatment for refractory ascites. Refractory ascites is defined as ascites that can not be mobilized or the early recurrence of which can not be satisfactorily prevented by medical therapy. Large volume paracentesis is the choice treatment for patients with tense ascites. Transjugular intrahepatic portosystemic shunt (TIPS) would be indicated when there is frequent (> 3 times per month) need for large volume paracentesis to manage ascites. Liver transplantation is indicated for refractory ascites treatment in patients that can not be underwent TIPS.
Primary Prevention
Effective measures for the primary prevention of ascites include hepatitis B vaccination, hepatitis C vaccination, alcohol abstinence, low fat diet, low sodium diet, and water restriction.
Secondary Prevention
Effective measures for the secondary prevention of ascites include water and sodium intake restriction, diuretic use, and antibiotic prophylaxis for spontaneous bacterial peritonitis (SBP).
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
About 20 BC, Aulus Cornelius Celsus (A.D. 30), a Roman encyclopedist explained in his book “De Medicina” three different types of fluid accumulation under the skin; which was called hydrops by Greeks. Celsus postulated that ascites is mostly secondary to quartan fever (malaria) in Rome. The principles of treatment for ascites were explained as thirst, rest, and abstinence. Drinking less fluid and sweating more, not with exercise, but with heated sand, or in the sweating-room, or with a dry oven and such- like where the other alternative therapies. In 1827, Ludwig van Beethoven involved in ascites and underwent large volumes of paracenteses. His physician write about him as “Beethoven had almost immediate relief, and when he saw the stream of water [during paracentesis], cried out that the operation made him think of Moses, who struck the rock with his staff and made the water gush forth.”
Historical Perspective
- About 20 BC, Aulus Cornelius Celsus (A.D. 30), a Roman encyclopedist explained in his book “De Medicina” three different types of fluid accumulation under the skin; which was called hydrops by Greeks. Celsus postulated that ascites is mostly secondary to quartan fever (malaria) in Rome.[1]
- Very tense belly with frequent noise of the wind movement sound – called tympanites.
- Uneven swelling and rising up in the body – called leukophlegmasia or hyposarca.
- The fluid gathering all together in the belly with visible movement along with the movements of body – called ascites.
- In 25 BC, Philip of Epirus, promised to cure the certain friend of king Antigonus with ascites. Philip cured the patient with devouring poultices and drinking his own urine. The basis of his treatment was thirst, rest, and abstinence.[1]
- 2000 years ago, Celsus, the Roman encyclopedist explain the first treatment procedure for ascites. He described a bronze tube with a specific collar to drain the abdominal fluid.[2]
- In 1906, Frederick Maberly reported large amounts of fluid drained from ascites patient abdomen for the first time. The procedure was consisted of simultaneous paracentesis while patients sit on adjacent shoeshine chairs.[3]
- In 1935, Daniel Darrow, an American pediatrician, suggested the role of sodium restriction in the treatment of ascites.[4]
- In 1936, Robert Alexander McCance, a British biochemist, found the passive nature of water movement and the the importance of sodium ion in ascites.[5]
- In 1947, John Layne, an American physician, described 20 patients with ascites which were treated by low sodium acid-ash diet.[6]
- In 1939, Hugh Butt, an American biochemist, postulated possible relation between serum albumin level and volume overload in patients with ascites.[7]
- In 1944, Charles Janeway, an American pathologist, suggested “high-salt” (300 mmol/L) albumin products as ascites treatment.[8]
- In 1945, George Thorn, an American biochemist, suggested “low-salt” (15 mmol/25 g) albumin products for volume overload treatment.[9]
- In 1949, William Faloon, an American biochemist, found that mercurial diuretics can increase the urinary sodium output dramatically, so can alleviate the fluid overload in ascites patients.[10]
- In 1957, Kagawa, an American biologist, discovered aldosterone.[11]
- In 1958, John Laragh, an American physician, discovered chlorothiazide diuretic as a potential treatment for ascites. Laragh proved complete cure of ascites in three out of nine patients, but they finally involved in hypokalemic hypochloremic alkalosis, though.[12] Various diuretics have been studied in treatment of ascites until now.
- In 1949, Thomas Chalmers, an American research fellow, mentioned that complete bed rest had an important role in the management of chronic liver diseases and ascites.[13]
- In 1949, Alexander Leaf, an American internist, revealed that passive contribution of water to fluid overload was the basis to introduce the fluid restriction as a treatment option for ascites.[14]
- From 1896 that Drummond and Morrison, British surgeons, reported the first surgical procedure of treatment of ascites, various surgical options were suggested for these patients.[15]
- In 1898, Talma, a German surgeon, evaluated the “omentopexy” procedure in a patient with ascites. In this procedure some adhesion were induced around the liver and portal system to prevent ascites formation. The patient was cured and lived until 2 years after surgery.[16]
- In 1943, Charles Fergusen, an American urologist, invented a surgical procedure in which a right nephrectomy was done first and then the peritoneum anastomosis with renal pelvis was performed. In this procedure the ascites fluid continuously drained via bladder and there was no need to frequent paracentesis.[17]
- In 1946, Crosby and Cooney, American surgeons, suggested the glass collar-button shaped instrument called “Crosby-Cooney button” to be placed in abdominal wall, allowing continuous drainage of ascites into subcutaneous tissues.[18]
- In 1966, Marshall Orloff, an American surgeon, first described side to side porto-caval shunt for treatment of ascites.[19]
- In 1974, Harry LeVeen, an American surgeon, suggested the “Peritoneo-venous shunt” procedure for treatment of ascites through drainage of fluid overload into the veins.[20]
- In 1982, Colapinto, a Canadian radiologist, first presented the transjugular intrahepatic portosystemic shunt (TIPS) for ascites treatment.[21]
- In 1967, Thomas Strazl, a British surgeon, performed the first liver transplant with more than 1 year surveillance in a patient with cirrhosis and ascites.[22]
Landmark Events in the Development of Treatment Strategies
| Ascites Treatment Developement | |||||||||||||||||||||||||||
| Ancient era | 2000 years ago Celsus A Roman encyclopedist | • Explain the first treatment procedure for ascites. | |||||||||||||||||||||||||
| Paracentesis era | 1906 Frederick Maberly A British physician | • First reported large amounts of fluid drained from ascites patient abdomen. | |||||||||||||||||||||||||
| Sodium era | 1935 Daniel Darrow An American pediatrician | • Suggested the role of sodium restriction in the treatment of ascites. | |||||||||||||||||||||||||
| 1936 Robert McCance A British biochemist | • Found the passive nature of water movement and the the importance of sodium ion in ascites. | ||||||||||||||||||||||||||
| 1947 John Layne An American physician | • Described 20 patients with ascites which were treated by low sodium acid-ash diet. | ||||||||||||||||||||||||||
| Albumin era | 1939 Hugh Butt An American biochemist | • Postulated possible relation between serum albumin level and volume overload in patients with ascites. | |||||||||||||||||||||||||
| 1944 Charles Janeway An American pathologist | • Suggested “high-salt” (300 mmol/L) albumin products as an ascites treatment. | ||||||||||||||||||||||||||
| 1945 George Thorn An American biochemist | • Suggested “low-salt” (15 mmol/25 g) albumin products for volume overload treatment. | ||||||||||||||||||||||||||
| Diuretic era | 1949 William Faloon An American biochemist | • Suggested mercurial diuretics for ascites treatment via increasing the urinary sodium output. | |||||||||||||||||||||||||
| 1957 Kagawa An American biologist | • Discovered aldosterone. | ||||||||||||||||||||||||||
| 1958 John Laragh An American physician | • Discovered chlorothiazide diuretic as a potential treatment for ascites. | ||||||||||||||||||||||||||
| Bed rest era | 1949 Thomas Chalmers An American research fellow | • Mentioned that complete bed rest had an important role in the management of chronic liver diseases and ascites. | |||||||||||||||||||||||||
| Fluid restriction era | 1949 Alexander Leaf An American internist | • Suggested passive contribution of water to fluid overload and fluid restriction as a treatment option for ascites. | |||||||||||||||||||||||||
| Surgery era | 1896 Drummond and Morrison British surgeons | • Reported the first surgical procedure of treatment of ascites. | |||||||||||||||||||||||||
| 1898 Talma A German surgeon | • Presented the “omentopexy” procedure in a patient with ascites. | ||||||||||||||||||||||||||
| 1943 Charles Fergusen An American urologist | • Invented a surgical procedure of nephrectomy and peritoneum anastomosis with renal pelvis to treat ascites. | ||||||||||||||||||||||||||
| 1946 Crosby and Cooney American surgeons | • Suggested the glass collar-button shaped instrument called “Crosby-Cooney button”. | ||||||||||||||||||||||||||
| Shunt era | 1966 Marshall Orloff An American surgeon | • First described side to side porto-caval shunt for treatment of ascites in patients. | |||||||||||||||||||||||||
| 1974 Harry LeVeen An American surgeon | • Suggested the “Peritoneo-venous shunt” for treatment of ascites by drainage of fluid into the veins. | ||||||||||||||||||||||||||
| 1982 Colapinto An American physician | • First presented the transjugular intrahepatic portosystemic shunt (TIPS) for ascites treatment. | ||||||||||||||||||||||||||
| Transplant era | 1967 Thomas Strazl A British surgeon | • Performed the first liver transplant with more than 1 year surveillance in a patient with cirrhosis and ascites. | |||||||||||||||||||||||||
- About 20 BC, Aulus Cornelius Celsus (A.D. 30), a Roman encyclopedist explained in his book “De Medicina” mentioned that ascites was relieved in slaves more easily than freemen. Because slaves can endure thirst, hunger, and other troublesome more than unserviceable freedom.
- The principles of treatment for ascites were explained as thirst, rest, and abstinence. Drinking less fluid and sweating more, not with exercise, but with heated sand, or in the sweating-room, or with a dry oven and such- like where the other alternative therapies.
- Pills composed of wormwood two parts and myrrh one part were given on an empty stomach to treat refractory types of ascites.
- Various remedies for ascites were postulated as the followings:
- The quantity of fluid input and output had to be measured and recorded daily.
- Abdomen circumference was also measured on a daily basis.[23]
Famous Cases
- In 1827, Ludwig van Beethoven involved in ascites and underwent large volumes of paracenteses. His physician write about him as “Beethoven had almost immediate relief, and when he saw the stream of water [during paracentesis], cried out that the operation made him think of Moses, who struck the rock with his staff and made the water gush forth.”
- The cirrhotic ascites, secondary to chronic alcohol and drug use, decreased lifespan in jazz musicians; result in dramatic influence on the history of jazz music.[25]
- Charlie Parker died from cirrhotic ascites at 35 years of age in 1955.
- John Coltrane (inventor of avant-garde jazz) died with ascites secondary to hepatitis B and hepatocellular carcinoma at 41 years of age in 1967.
- Stan Getz in 1990 and Steve Lacy in 2004, both saxophone stylists, died from hepatocellular carcinoma.
- Bill Evans, a lyrical pianist, died of cirrhotic complications.
- The famous Four Brothers from the Woody Herman band (Stan Getz, Al Cohn, Serge Chaloff, and Zoot Sims) all died from cirrhosis complications.
References
- ↑ 1.0 1.1 Jarcho, Saul (1958). “Ascites as described by Aulus Cornelius Celsus (ca. A.D. 30)”. The American Journal of Cardiology. 2 (4): 507–508. doi:10.1016/0002-9149(58)90339-4. ISSN 0002-9149.
- ↑ Mencken, H. L.; Conn, Harold O. (1985). “The paracentesis pendulum”. Hepatology. 5 (3): 521–522. doi:10.1002/hep.1840050331. ISSN 0270-9139.
- ↑ Maberly, Frederick (April 21, 1906). “A case of ascites tapped 69 times”. The Lancet: 1108.
- ↑ Darrow, Daniel C.; Yannet, Herman (1935). “THE CHANGES IN THE DISTRIBUTION OF BODY WATER ACCOMPANYING INCREASE AND DECREASE IN EXTRACELLULAR ELECTROLYTE”. Journal of Clinical Investigation. 14 (2): 266–275. doi:10.1172/JCI100674. ISSN 0021-9738.
- ↑ McCance, R. A. (1936). “Experimental Sodium Chloride Deficiency in Man”. Proceedings of the Royal Society B: Biological Sciences. 119 (814): 245–268. doi:10.1098/rspb.1936.0009. ISSN 0962-8452.
- ↑ LAYNE JA, SCHEMM FR (1947). “The use of a high fluid intake and a low-sodium acid-ash diet in the management of portal cirrhosis with ascites”. Gastroenterology. 9 (6): 705–17 [Discussion 749–53]. PMID 18897334.
- ↑ Butt, Hugh R. (1939). “PLASMA PROTEIN IN HEPATIC DISEASE”. Archives of Internal Medicine. 63 (1): 143. doi:10.1001/archinte.1939.00180180153010. ISSN 0730-188X.
- ↑ Janeway CA, Gibson ST, Woodruff LM, Heyl JT, Bailey OT, Newhouser LR (1944). “CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. VII. CONCENTRATED HUMAN SERUM ALBUMIN”. J Clin Invest. 23 (4): 465–90. doi:10.1172/JCI101514. PMC 435363. PMID 16695125.
- ↑ Thorn GW, Armstrong SH, Davenport VD, Woodruff LM, Tyler FH (1945). “CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION XXX. THE USE OF SALT-POOR CONCENTRATED HUMAN SERUM ALBUMIN SOLUTION IN THE TREATMENT OF CHRONIC BRIGHT’S DISEASE”. J Clin Invest. 24 (6): 802–28. doi:10.1172/JCI101666. PMC 435518. PMID 16695276.
- ↑ Faloon, William W.; Eckhardt, Richard D.; Cooper, Arnold M.; Davidson, Charles S. (1949). “THE EFFECT OF HUMAN SERUM ALBUMIN, MERCURIAL DIURETICS, AND A LOW SODIUM DIET ON SODIUM EXCRETION IN PATIENTS WITH CIRRHOSIS OF THE LIVER 123”. Journal of Clinical Investigation. 28 (4): 595–602. doi:10.1172/JCI102109. ISSN 0021-9738.
- ↑ Kagawa, C. M.; Cella, J. A.; Van Arman, C. G. (1957). “Action of New Steroids in Blocking Effects of Aldosterone and Deoxycorticosterone on Salt”. Science. 126 (3281): 1015–1016. doi:10.1126/science.126.3281.1015. ISSN 0036-8075.
- ↑ Laragh, John H. (1958). “EFFECT OF CHLOROTHIAZIDE ON ELECTROLYTE TRANSPORT IN MAN”. Journal of the American Medical Association. 166 (2): 145. doi:10.1001/jama.1958.02990020033006. ISSN 0002-9955.
- ↑ Chalmers, Thomas C.; Davidson, Charles S. (1949). “A Survey of Recent Therapeutic Measures in Cirrhosis of the Liver”. New England Journal of Medicine. 240 (12): 449–455. doi:10.1056/NEJM194903242401202. ISSN 0028-4793.
- ↑ Leaf, Alexander; Couter, William T.; Lutchansky, Marion; Reimer, Ann (1949). “EVIDENCE THAT RENAL SODIUM EXCRETION BY NORMAL HUMAN SUBJECTS IS REGULATED BY ADRENAL CORTICAL ACTIVITY 1”. Journal of Clinical Investigation. 28 (5 Pt 2): 1067–1081. doi:10.1172/JCI102139. ISSN 0021-9738.
- ↑ Drummond, D; Morison, R (1896). “Case of ascites due to cirrhosis of liver cured by operation”. British Medical Journal. 2: 728.
- ↑ Talma, S (1898). “Chirurgische Offnung neuer Seitenbahnen für das Blut der Vena porta”. Berlin klinik Wchnschrer. 35: 833–836.
- ↑ Ferguson, Charles (1943). “Ascites: An Operation for its Relief. A Case Report”. The Journal of Urology. 50 (2): 164–168. doi:10.1016/S0022-5347(17)70432-6. ISSN 0022-5347.
- ↑ Crosby, Roy C.; Cooney, Edward A. (1946). “Surgical Treatment of Ascites”. New England Journal of Medicine. 235 (16): 581–585. doi:10.1056/NEJM194610172351602. ISSN 0028-4793.
- ↑ Orloff, Marshall J. (1966). “Effect of side to side portacaval shunt on intractable ascites, sodium excretion, and aldosterone metabolism in man”. The American Journal of Surgery. 112 (2): 287–298. doi:10.1016/0002-9610(66)90021-3. ISSN 0002-9610.
- ↑ Leveen HH, Christoudias G, Ip M, Luft R, Falk G, Grosberg S (1974). “Peritoneo-venous shunting for ascites”. Ann Surg. 180 (4): 580–91. PMC 1344147. PMID 4415019.
- ↑ Colapinto RF, Stronell RD, Birch SJ, Langer B, Blendis LM, Greig PD; et al. (1982). “Creation of an intrahepatic portosystemic shunt with a Grüntzig balloon catheter”. Can Med Assoc J. 126 (3): 267–8. PMC 1862861. PMID 6977404.
- ↑ Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB; et al. (1968). “Orthotopic homotransplantation of the human liver”. Ann Surg. 168 (3): 392–415. PMC 1387344. PMID 4877589.
- ↑ “CelsusDe Medicina”. New England Journal of Medicine. 213 (20): 991–991. 1935. doi:10.1056/NEJM193511142132014. ISSN 0028-4793.
- ↑ Adams, Paul C. (1987). “Historical hepatology: Ludwig van Beethoven”. Journal of Gastroenterology and Hepatology. 2 (4): 375–379. doi:10.1111/j.1440-1746.1987.tb00176.x. ISSN 0815-9319.
- ↑ Adams PC (2009). “The lost years: the impact of cirrhosis on the history of jazz”. Can J Gastroenterol. 23 (6): 405–6. PMC 2721805. PMID 19543568.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Ascites may be classified according to etiology into four groups include: portal hypertension associated, hypoalbuminemia associated, peritoneal disease associated, and other diseases associated. Ascites is also classified based on the serum-ascites albumin gradient (SAAG) as two subtypes include transudate – SAAG > 1.1 g/dL and exudate – SAAG < 1.1 g/dL.
Classification
Ascites may be classified according to etiology into four groups:[1]
Ascites is also classified based on the serum-ascites albumin gradient (SAAG) as two subtypes:[2]
- Transudate – SAAG > 1.1 g/dL
- Exudate – SAAG < 1.1 g/dL
References
- ↑ Moore KP, Aithal GP (2006). “Guidelines on the management of ascites in cirrhosis”. Gut. 55 Suppl 6: vi1–12. doi:10.1136/gut.2006.099580. PMC 1860002. PMID 16966752.
- ↑ Hou W, Sanyal AJ (2009). “Ascites: diagnosis and management”. Med. Clin. North Am. 93 (4): 801–17, vii. doi:10.1016/j.mcna.2009.03.007. PMID 19577115.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Ascites is the excess accumulation of fluid in the peritoneal cavity. The fluid can be defined as transudate or exudate. Amounts of up to 25 liters are fully possible. Roughly, transudates are a result of increased pressure in the portal vein (> 8 mmHg), such as cirrhosis; while exudates are actively secreted fluid due to inflammation or malignancy. The most useful measure is the difference between ascitic and serum albumin concentrations. A difference of less than 1.1 g/dl (10 g/L) implies an exudate. There is no genetic background for ascites. On gross pathology, clear to pale yellow fluid accumulation in peritoneal space are characteristic findings of ascites under normal condition, but it may be chylous, psudochylous, or bloody.
Pathophysiology
Pathogenesis
- Ascites is the excess accumulation of fluid in the peritoneal cavity. The fluid can be defined as a transudate or an exudate. Amounts of up to 25 liters are fully possible.[1]
- Roughly, transudates are a result of increased pressure in the portal vein (> 8 mmHg), such as cirrhosis; while exudates are actively secreted fluid due to inflammation or malignancy.
- Exudates:
- High protein
- High lactate dehydrogenase (LDH)
- Low pH (< 7.30)
- Low glucose level
- High white blood cells count
- Transudates:
- Low protein (< 30 g/L)
- Low lactate dehydrogenase (LDH)
- High pH
- Normal glucose
- Fewer than 1 white blood cell per 1000 mm³
Serum Albumin Ascites Gradiant (SAAG)
- The most useful measure is the difference between ascitic and serum albumin concentrations.
- A difference of less than 1.1 g/dl (10 g/L) implies an exudate.
Cirrhotic Ascites
- The main pathophysiology of ascites in cirrhotic patients consists of three interrelated mechanisms, include:[2]
- There is a nitric oxide overload in cirrhotic patients from an unknown source. Therefore, they involved in hypovolemia secondary to the systemic vasodilation.[3]
- The vasodilation induced by nitric oxide would trigger the stimulation of juxta-glumerular system to upregulate antidiuretic hormone (ADH) and sympathetic drive.[4] Excess ADH causes water retention and volume overload.[5]
- Despite the normal physiology of vessels, angiotensin would not cause vasoconstriction in cirrhotic patients and vasodilation becomes perpetuated.[6]
- Portal hypertension leads to more production of lymph, to the extend of lymphatic system overload. Then, the lymphatic overflow will directed into to peritoneal cavity, forming ascites.[7]
Non-Cirrhotic Ascites
- Peritoneal malignancy produces some protein factors into the peritoneum, which may lead to osmotic drainage of water and fluid accumulation. Tuberculosis and other forms of ascites are induced through the same mechanism and osmotic fluid shift.[8]
- Pancreatic and biliary ascites are induced through leakage of pancreatic secretions or bile into the peritoneal cavity, which may lead to inflammatory fluid shift and accumulation.
| ↑Renin-angiotensin system | ↑Sympathetic nervous system | ↑Antidiuretic hormone | |||||||||||||||||||||||||||||||
| Systemic circulation | Renal circulation | ||||||||||||||||||||||||||||||||
| Arterial vasoconstriction | ↑Tubular Na and H2O reabsorbtion | Renal vasoconstriction | |||||||||||||||||||||||||||||||
| Arterial hypertension | Na and H2O excretion | Hepatorenal syndrome | |||||||||||||||||||||||||||||||
| Fluid overload | Dilutional hyponatremia | ||||||||||||||||||||||||||||||||
| Ascites formation | |||||||||||||||||||||||||||||||||
Genetics
- There is no genetic background for ascites.
- Ascites syndrome, also called pulmonary hypertension, is in fact a genetic disorder in broilers and poultry.[9]
Associated Conditions
Associated conditions with ascites are as following:[10]
- Cirrhosis
- Heart failure
- Portal hypertension
- Kwashiorkor
- Viral hepatitis
- Pancreatic disease
- Biliary disease
Gross Pathology
- On gross pathology, clear to pale yellow fluid accumulation in peritoneal space are characteristic findings of ascites under normal condition.[11]
Chylous ascites
- Chylous ascites gross pathology is milky presentation of ascites fluid, which is reflective of high amounts of chylomicrons.[12]
- On gross pathology, milky appearance of ascitic fluid is characteristics of the followings:[13]
Pseudochylous ascites
- Pseudochylous is the condition in which on gross pathology the ascitic fluid appearance is cloudy and/or turbid.
- The following conditions can lead to pseudochylous:[14]
Bloody ascites
- On gross pathology, bloody appearance of ascitic fluid is characteristics of the followings:[15]
- Benign or malignant tumors
- Hemorrhagic pancreatitis
- Perforated ulcer
Microscopic Pathology

- On microscopic histopathological analysis, characteristic findings of cirrhosis, as the most common cause of ascites, are based on Robbins definition (all three is needed for diagnosis):[17]
References
- ↑ Runyon BA (2009). “Management of adult patients with ascites due to cirrhosis: an update”. Hepatology. 49 (6): 2087–107. doi:10.1002/hep.22853. PMID 19475696.
- ↑ Giefer, Matthew J; Murray, Karen F; Colletti, Richard B (2011). “Pathophysiology, Diagnosis, and Management of Pediatric Ascites”. Journal of Pediatric Gastroenterology and Nutrition. 52 (5): 503–513. doi:10.1097/MPG.0b013e318213f9f6. ISSN 0277-2116.
- ↑ La Villa, Giorgio; Gentilini, Paolo (2008). “Hemodynamic alterations in liver cirrhosis”. Molecular Aspects of Medicine. 29 (1–2): 112–118. doi:10.1016/j.mam.2007.09.010. ISSN 0098-2997.
- ↑ Leiva JG, Salgado JM, Estradas J, Torre A, Uribe M (2007). “Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents”. Ann Hepatol. 6 (4): 214–21. PMID 18007550.
- ↑ Bichet, Daniel (1982). “Role of Vasopressin in Abnormal Water Excretion in Cirrhotic Patients”. Annals of Internal Medicine. 96 (4): 413. doi:10.7326/0003-4819-96-4-413. ISSN 0003-4819.
- ↑ Hennenberg, M.; Trebicka, J.; Kohistani, A. Z.; Heller, J.; Sauerbruch, T. (2009). “Vascular hyporesponsiveness to angiotensin II in rats with CCl4-induced liver cirrhosis”. European Journal of Clinical Investigation. 39 (10): 906–913. doi:10.1111/j.1365-2362.2009.02181.x. ISSN 0014-2972.
- ↑ Laine GA, Hall JT, Laine SH, Granger J (1979). “Transsinusoidal fluid dynamics in canine liver during venous hypertension”. Circ. Res. 45 (3): 317–23. PMID 572270.
- ↑ Goodman GM, Gourley GR (1988). “Ascites complicating ventriculoperitoneal shunts”. J. Pediatr. Gastroenterol. Nutr. 7 (5): 780–2. PMID 3054040.
- ↑ Pakdel, A.; van Arendonk, J.A.M.; Vereijken, A.L.J.; Bovenhuis, H. (2010). “Genetic parameters of ascites-related traits in broilers: effect of cold and normal temperature conditions”. British Poultry Science. 46 (1): 35–42. doi:10.1080/00071660400023938. ISSN 0007-1668.
- ↑ Moore KP, Aithal GP (2006). “Guidelines on the management of ascites in cirrhosis”. Gut. 55 Suppl 6: vi1–12. doi:10.1136/gut.2006.099580. PMC 1860002. PMID 16966752.
- ↑ Huang LL, Xia HH, Zhu SL (2014). “Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites”. J Clin Transl Hepatol. 2 (1): 58–64. doi:10.14218/JCTH.2013.00010. PMC 4521252. PMID 26357618.
- ↑ Fukunaga, Naoto; Shomura, Yu; Nasu, Michihiro; Okada, Yukikatsu (2011). “Chylous Ascites as a Rare Complication After Abdominal Aortic Aneurysm Surgery”. Southern Medical Journal. 104 (5): 365–367. doi:10.1097/SMJ.0b013e3182142b7d. ISSN 0038-4348.
- ↑ Tarn, A. C.; Lapworth, R. (2010). “Biochemical analysis of ascitic (peritoneal) fluid: what should we measure?”. Annals of Clinical Biochemistry. 47 (5): 397–407. doi:10.1258/acb.2010.010048. ISSN 0004-5632.
- ↑ Runyon BA, Akriviadis EA, Keyser AJ (1991). “The opacity of portal hypertension-related ascites correlates with the fluid’s triglyceride concentration”. Am. J. Clin. Pathol. 96 (1): 142–3. PMID 2069132.
- ↑ Runyon BA, Hoefs JC, Morgan TR (1988). “Ascitic fluid analysis in malignancy-related ascites”. Hepatology. 8 (5): 1104–9. PMID 3417231.
- ↑ “File:Cirrhosis high mag.jpg – Libre Pathology”.
- ↑ Mitchell, Richard (2012). Pocket companion to Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Elsevier Saunders. ISBN 978-1416054542.
Causes
Common Causes | System based | Alphabetical order
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2], M.Umer Tariq [3], Carlos A Lopez, M.D. [4]
Overview
Life-threatening causes of ascites are acute liver failure, hepatic failure, and hepatorenal syndrome. Common causes of ascites are Budd-Chiari syndrome, malignancy, and cirrhosis. Less common causes of ascites are the conditions which may lead to fetal ascites, neonatal ascites, and infantile ascites.
Causes
Life Threatening Causes
Common Causes
- Budd-Chiari syndrome
- Cancer
- Cirrhosis
- Constrictive pericarditis
- Heart failure
- Nephrotic syndrome
- Pancreatitis
- Serositis
- Tuberculosis
Less common causes
- Gastrointestinal disorders
- Infection
- Parvovirus
- Syphilis
- Cytomegalovirus
- Toxoplasmosis
- Acute maternal hepatitis
- Genitourinary disorders
- Chylous ascites
- Cardiac disorders
- Chromosomal abnormalities
- Neoplasm
- Hematologic
- Metabolic disease
- Other
- Maternal/fetal abuse
- Idiopathic
- Hepatobiliary disorders
- Gastrointestinal disorders
- Chylous ascites
- Parenteral nutrition extravasation
- Metabolic disease
- Genitourinary disorders
- Cardiac
- Hematologic
- Other
- Cutis marmota telangictatica congenita
- Intravenous vitamin E
- Pseudo-ascites
- Small bowel duplication
- Abdominal trauma
- Idiopathic
- Hepatobiliary disorders
- Gastrointestinal disorders
- Acute appendicitis
- Intestinal atresia
- Pancreatitis
- Pyloric duplication
- Serositis
- Chylous ascites
- Intestinal lymphangiectasia
- Lymphatic duct obstruction
- Lymphatic duct trauma
- Parenteral nutrition extravasation
- Neoplasm
- Lymphoma
- Wilm tumor
- Clear cell renal sarcoma
- Glioma
- Germ cell tumor
- Ovarian tumor
- Mesothelioma
- Neuroblastoma
- Metabolic disease
- Genitourinary disorders
- Cardiac
- Pseudo-ascites
- Celiac disease
- Cystic mesothelioma
- Omental cyst
- Ovarian cyst
- Other
Causes by Organ System
Causes in Alphabetical Order
References
- ↑ Sun CC, Keene CL, Nagey DA (1990). “Hepatic fibrosis in congenital cytomegalovirus infection: with fetal ascites and pulmonary hypoplasia”. Pediatr Pathol. 10 (4): 641–6. PMID 2164662.
- ↑ Stocker JT (1985). “Congenital cytomegalovirus infection presenting as massive ascites with secondary pulmonary hypoplasia”. Hum. Pathol. 16 (11): 1173–5. PMID 2997019.
- ↑ Patton WL, Lutz AM, Willmann JK, Callen P, Barkovich AJ, Gooding CA (1998). “Systemic spread of meconium peritonitis”. Pediatr Radiol. 28 (9): 714–6. doi:10.1007/s002470050449. PMID 9732503.
- ↑ Dirkes K, Crombleholme TM, Craigo SD, Latchaw LA, Jacir NN, Harris BH, D’Alton ME (1995). “The natural history of meconium peritonitis diagnosed in utero”. J. Pediatr. Surg. 30 (7): 979–82. PMID 7472957.
- ↑ Son M, Walsh CA, Baxi LV (2010). “Prenatal diagnosis of urinary ascites in a fetus with meningomyelocele”. Fetal. Diagn. Ther. 28 (1): 61–4. doi:10.1159/000312405. PMID 20389051.
- ↑ Spriggs, DW; Brantley, RE (1977). “Thoracic and abdominal extravasation: a complication of hyperalimentation in infants”. American Journal of Roentgenology. 128 (3): 419–422. doi:10.2214/ajr.128.3.419. ISSN 0361-803X.
- ↑ Hepworth RC, Milstein JM (1984). “The transected urachus: an unusual cause of neonatal ascites”. Pediatrics. 73 (3): 397–400. PMID 6701064.
- ↑ Keller M, Scholl-Buergi S, Sergi C, Theurl I, Weiss G, Unsinn KM, Trawöger R (2008). “An unusual case of intrauterine symptomatic neonatal liver failure”. Klin Padiatr. 220 (1): 32–6. doi:10.1055/s-2007-970591. PMID 18172830.
- ↑ Gillan JE, Lowden JA, Gaskin K, Cutz E (1984). “Congenital ascites as a presenting sign of lysosomal storage disease”. J. Pediatr. 104 (2): 225–31. PMID 6420531.
- ↑ Gil Z, Beni-Adani L, Siomin V, Nagar H, Dvir R, Constantini S (2001). “Ascites following ventriculoperitoneal shunting in children with chiasmatic-hypothalamic glioma”. Childs Nerv Syst. 17 (7): 395–8. PMID 11465792.
- ↑ Goodman GM, Gourley GR (1988). “Ascites complicating ventriculoperitoneal shunts”. J. Pediatr. Gastroenterol. Nutr. 7 (5): 780–2. PMID 3054040.
- ↑ Zegarra A, García C, Piscoya A, de Los Ríos R, Luis Pinto J, Mayo N, Huerta-Mercado J (2009). “[Eosinophilic enteritis as a rare cause of ascites: case report]”. Rev Gastroenterol Peru (in Spanish; Castilian). 29 (3): 272–5. PMID 19898601.
- ↑ Caine Y, Deckelbaum RJ, Weizman Z, Lijovetsky G, Schiller M (1984). “Congenital hepatic fibrosis–unusual presentations”. Arch. Dis. Child. 59 (11): 1094–6. PMC 1628818. PMID 6391392.
Differentiating Ascites from other Conditions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Diseases that cause ascites should differentiate from each others, such as cirrhosis, Alcoholic hepatitis, Budd-Chiari syndrome, Constrictive pericarditis, Heart failure, Myxedema, Cancer, Nephrotic syndrome, Pancreatitis, Serositis, and Tuberculosis. The ascites may be transudate (serum-ascites albumin gradient [SAAG] ≥ 1.1 g/dL) or exudate (serum-ascites albumin gradient [SAAG] < 1.1 g/dL).
Differentiating Other Diseases Caused Ascites
- Diseases that cause ascites should differentiate from each others, such as cirrhosis, Alcoholic hepatitis, Budd-Chiari syndrome, Constrictive pericarditis, Heart failure, Myxedema, Cancer, Nephrotic syndrome, Pancreatitis, Serositis, and Tuberculosis.
- The ascites may be transudate (serum-ascites albumin gradient [SAAG] ≥ 1.1 g/dL) or exudate (serum-ascites albumin gradient [SAAG] < 1.1 g/dL).
| Type | Diseases | History and Symptoms | Physical Examination | Laboratory Findings | Other Findings | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GI symptoms | Extra-GI symptoms | Liver function test | Biochemical test | ||||||||||||||||||||
| Jaundice | Abdominal pain | Hematemesis | Nausea | Weight loss | Dyspnea | Cough | Chest pain | Fever | Spider angioma | Abdominal tenderness | Jugular venous distention | Pitting edema | Muffled heart sounds | ALT | AST | Bili | Amylase /Lipase | Cr | ESR | Na-K | |||
| Transudate
(SAAG≥ 1.1g/dL) |
Cirrhosis | ++ | + | + | + | + | – | – | – | – | + | + | – | – | – | ↑↑ | ↑↑ | ↑↑ | Normal | Normal | Normal | Normal | |
| Alcoholic hepatitis | – | – | – | + | + | – | – | – | + | – | – | – | – | – | ↑ | ↑↑↑ | Normal | Normal | Normal | Normal | Normal | ||
| Budd-Chiari syndrome | – | + | – | + | + | – | – | – | + | – | – | – | – | – | ↑ | ↑ | Normal | Normal | Normal | ↑ | Normal | ||
| Constrictive pericarditis | – | – | – | – | – | + | – | + | + | – | – | ++ | – | + | Normal | Normal | Normal | Normal | Normal | ↑ | Normal | ||
| Heart failure | – | – | – | – | + | + | + | + | – | – | – | + | + | – | Normal | Normal | Normal | Normal | Normal | Normal | ↑ |
| |
| Myxedema | – | – | – | – | – | + | – | – | – | – | – | – | ++ | – | Normal | Normal | Normal | Normal | Normal | Normal | ↓ | ||
| Portal hypertension | +/- | + | + | + | + | – | – | – | – | + | – | – | – | – | ↑ | ↑ | ↑ | Normal | ↑ | Normal | Normal | ||
| Exudate
(SAAG< 1.1g/dL) |
Cancer | + | + | – | + | ++ | – | – | – | – | – | – | – | – | – | Normal | Normal | Normal | Normal | Normal | ↑↑ | Normal | – |
| Nephrotic syndrome | – | – | – | + | – | – | – | – | – | – | – | – | ++ | – | Normal | Normal | Normal | Normal | ↑↑ | ↑ | ↑↑ | ||
| Pancreatitis | +/- | +++ | – | ++ | – | – | – | + | + | – | ++ | – | – | – | Normal | Normal | Normal | ↑↑ | Normal | ↑ | Normal | ||
| Serositis | – | + | – | + | + | – | – | +/- | + | – | + | – | – | – | Normal | Normal | Normal | Normal | Normal | ↑ | Normal | – | |
| Tuberculosis | – | + | – | + | + | ++ | ++ | ++ | +/- | – | + | – | – | – | Normal | Normal | Normal | Normal | Normal | ↑↑ | Normal | ||
References
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
The incidence of ascites is approximately 60,000 per 100,000 individuals with cirrhosis worldwide. The incidence of ascites is approximately 75,000 per 100,000 cirrhotic individuals with a mortality rate of 50%, within 3 years. Patients of all age groups may develop ascites. Cirrhotic ascites usually affects individuals of the non-Hispanic blacks and Mexican Americans race. Males are more commonly affected by cirrhotic ascites than females. The male to female ratio is approximately 2.5 to 1.
Epidemiology and Demographics
Incidence
- The incidence of ascites is approximately 60,000 per 100,000 individuals with cirrhosis worldwide.[1]
- Among patients with ascites 8,000 to 35,000 per 100,000 individuals would involve in spontaneous bacterial peritonitis (SBP).[2]
- The incidence of chylous ascites is approximately 5 per 100,000 individuals worldwide.[3]
Prevalence
- The prevalence of ascites is approximately 75,000 per 100,000 individuals with cirrhosis in Western countries.[4]
- The prevalence of cirrhosis, malignancy, heart failure, tuberculosis, and nephrotic syndrome is approximately 81,000, 10,000, 3,000, 2,000, and 1,000 per 100,000 individuals with ascites worldwide, respectively.[5]
Case-fatality rate/Mortality rate
- The incidence of ascites is approximately 75,000 per 100,000 cirrhotic individuals with a mortality rate of 50%, within 3 years.[6]
- Survival from ascites majorly depends on severity of portal hypertension, liver failure, and circulation dysfunction.[4]
Age
- Patients of all age groups may develop ascites.
Race
- There is no racial predilection to ascites.
- Cirrhotic ascites usually affects individuals of the non-Hispanic blacks and Mexican Americans race.[7]
Gender
- Ascites affects men and women equally.
- Males are more commonly affected by cirrhotic ascites than females. The male to female ratio is approximately 2.5 to 1.[7]
Region
- Cirrhotic ascites is a common disease that tends to affect people below the poverty and with low education level.[7]
References
- ↑ Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C (1987). “Compensated cirrhosis: natural history and prognostic factors”. Hepatology. 7 (1): 122–8. PMID 3804191.
- ↑ Caly WR, Strauss E (1993). “A prospective study of bacterial infections in patients with cirrhosis”. J. Hepatol. 18 (3): 353–8. PMID 8228129.
- ↑ Press OW, Press NO, Kaufman SD (1982). “Evaluation and management of chylous ascites”. Ann. Intern. Med. 96 (3): 358–64. PMID 7059101.
- ↑ 4.0 4.1 Pedersen JS, Bendtsen F, Møller S (2015). “Management of cirrhotic ascites”. Ther Adv Chronic Dis. 6 (3): 124–37. doi:10.1177/2040622315580069. PMC 4416972. PMID 25954497.
- ↑ Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG (1992). “The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites”. Ann. Intern. Med. 117 (3): 215–20. PMID 1616215.
- ↑ Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura PJ, Cárdenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J (2001). “A prognostic model for predicting survival in cirrhosis with ascites”. J. Hepatol. 34 (1): 46–52. PMID 11211907.
- ↑ 7.0 7.1 7.2 Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML (2015). “The Epidemiology of Cirrhosis in the United States: A Population-based Study”. J. Clin. Gastroenterol. 49 (8): 690–6. doi:10.1097/MCG.0000000000000208. PMID 25291348.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
The most potent risk factor in the development of ascites is cirrhosis. Other risk factors include malignancy, heart failure, and tuberculosis. Common risk factors in the development of asctes include acute liver failure, hepatorenal syndrome, liver fibrosis, Budd-Chiari syndrome, constrictive pericarditis, nephrotic syndrome, pancreatitis, and serositis.
Risk Factors
- The most potent risk factor in the development of ascites is cirrhosis. Other risk factors include malignancy, heart failure, and tuberculosis.
- Common risk factors in the development of asctes include acute liver failure, hepatorenal syndrome, liver fibrosis, Budd-Chiari syndrome, constrictive pericarditis, nephrotic syndrome, pancreatitis, and serositis.
Common Risk Factors
- Common risk factors in the development of cirrhosis include:[1]
Less Common Risk Factors
- Less common risk factors in the development of ascites include:[2]
- Amebiasis
- Ascariasis
- Brucellosis
- HIV infection
- Pelvic inflammatory disease
- Pseudomembranous colitis
- Salmonellosis
- Whipple’s disease
- Amyloidosis
- Castleman’s syndrome
- Extramedullary hematopoiesis
- Hemophagocytic syndrome
- Histiocytosis X
- Leukemia
- Lymphoma
- Mastocytosis
- Multiple myeloma
- Abdominal pregnancy
- Crohn’s disease
- Endometriosis
- Gaucher’s disease
- Lymphangioleiomyomatosis
- Myxedema
- Ovarian hyperstimulation syndrome
- POEMS syndrome
- Systemic lupus erythematosus
- Ventriculoperitoneal shunt
- Chlamydia peritonitis
References
- ↑ Moore CM, Van Thiel DH (2013). “Cirrhotic ascites review: Pathophysiology, diagnosis and management”. World J Hepatol. 5 (5): 251–63. doi:10.4254/wjh.v5.i5.251. PMC 3664283. PMID 23717736.
- ↑ Runyon BA (1998). “Management of adult patients with ascites caused by cirrhosis”. Hepatology. 27 (1): 264–72. doi:10.1002/hep.510270139. PMID 9425946.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for ascites.
Screening
- There is insufficient evidence to recommend routine screening for ascites.
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
More than half of the patients with cirrhosis would involve with ascites during the disease. If left untreated, 11.4% of patients with cirrhotic ascites may progress to develop hepatorenal syndrome during 5 years. Common complications of ascites include spontaneous bacterial peritonitis (SBP), dilutional hyponatremia, and hepatorenal syndrome. Prognosis is generally poor, and the 5-year survival rate of patients with cirrhotic ascites is approximately 56.6%.
Natural History, Complications, and Prognosis
Ascites may contribute to three grades:[1]
- Grade 1: Mild accumulation of fluid in abdomen, which is only visible on ultrasound.
- Grade 2: Moderate accumulation of fluid in abdomen, which is detectable with flank bulging and shifting dullness.
- Grade 3: Severe accumulation of fluid in abdomen, which is directly visible with fluid thrill.
Natural History
- More than half of the patients with cirrhosis would involve with ascites during the disease.
- The symptoms of refractory ascites typically develop in 11.3% of patients during 5 years of cirrhosis.
- If left untreated, 37.1% of patients with cirrhotic ascites may progress to develop dilutional hyponatremia during 5 years.
- If left untreated, 11.4% of patients with cirrhotic ascites may progress to develop hepatorenal syndrome during 5 years.[2]
Complications
- Common complications of ascites include:[3]
Prognosis
- Prognosis is generally poor, and the 5-year survival rate of patients with cirrhotic ascites is approximately 56.6%.
- The presence of spontaneous bacterial peritonitis (SBP), dilutional hyponatremia, and hepatorenal syndrome is associated with a particularly poor prognosis among patients with cirrhotic ascites.[2]
References
- ↑ Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66. PMID 12830009.
- ↑ 2.0 2.1 Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R (2006). “Natural history of patients hospitalized for management of cirrhotic ascites”. Clin. Gastroenterol. Hepatol. 4 (11): 1385–94. doi:10.1016/j.cgh.2006.08.007. PMID 17081806.
- ↑ Pedersen JS, Bendtsen F, Møller S (2015). “Management of cirrhotic ascites”. Ther Adv Chronic Dis. 6 (3): 124–37. doi:10.1177/2040622315580069. PMC 4416972. PMID 25954497.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Paracentesis | Electrocardiogram | Chest X Ray | CT Scan | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
